Polycythemia Vera
Advertisement
Rusfertide quickly induced hematocrit control and maintained improved levels over time in patients with polycythemia vera.
Researchers analyzed PV patients allocated to the ropeginterferon alfa-2b arm of the PROUD-PV/CONTINUATION-PV studies.
CR rates were comparable in both treatment groups, but OS was superior in the ruxolitinib group.
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Advertisement
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Researchers presented data from the randomized withdrawal phase of the study at the SOHO Annual Meeting.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Dr. Harrison discusses survey results from the LANDMARK survey in patients with polycythemia vera and their physicians.
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
The trial included patients with PV who had at least three therapeutic phlebotomies in the 28 weeks prior to enrollment.
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Dr. Krecak presented the research during the 2023 EHA Congress.
The main aim of treatment is preventing thrombotic complications.
The FDA could not approve the application in its current form and identified additional requirements for approval.
Hematocrit control was “suboptimal” in more than half of patients with high-risk polycythemia vera.
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Patients with MPN have a high risk of death from cardiovascular causes.
Srdan Verstovsek, MD, discusses the phase III VERIFY trial of rusfertide in patients with polycythemia vera.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.